Table 1.
Characteristics of study group.
Table 2.
ARV regimens directly before the switch to DLT/DRV/r.
Table 3.
Reasons for the introduction of DTV/DRV/r.
Fig 1.
Algorithm of the study population.
DTG/DRV/r = dolutegravir and ritonavir-boosted darunavir.
Fig 2.
Number of subjects with lipids abnormality at baseline and week 48 TC -total cholesterol, LDL-C—Low-density lipoprotein cholesterol, TG -triglyceridep>0.05 for all comparison.
Table 4.
Comparison of results before the introduction of DTG/DRV/r therapy and at 48 weeks of treatment.
Table 5.
Lipids changes during therapy in subgroups according to the prior TDF intake.